Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organophosphate Poisoning | 6 | 2016 | 14 | 2.050 |
Why?
|
| Antidotes | 7 | 2023 | 21 | 1.510 |
Why?
|
| Professional Competence | 4 | 2020 | 93 | 1.440 |
Why?
|
| Interviews as Topic | 5 | 2020 | 526 | 1.410 |
Why?
|
| Pesticides | 4 | 2016 | 56 | 1.240 |
Why?
|
| Personnel Selection | 4 | 2020 | 56 | 1.060 |
Why?
|
| Emergency Medicine | 7 | 2022 | 190 | 1.050 |
Why?
|
| Aryldialkylphosphatase | 3 | 2010 | 19 | 0.940 |
Why?
|
| Internship and Residency | 7 | 2020 | 811 | 0.870 |
Why?
|
| Neuromuscular Junction | 2 | 2016 | 77 | 0.800 |
Why?
|
| Education, Medical, Graduate | 4 | 2019 | 354 | 0.770 |
Why?
|
| Dichlorvos | 5 | 2014 | 15 | 0.730 |
Why?
|
| Poisoning | 5 | 2023 | 32 | 0.700 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2010 | 21 | 0.670 |
Why?
|
| Insecticides | 5 | 2012 | 44 | 0.670 |
Why?
|
| Cholinesterase Inhibitors | 4 | 2014 | 47 | 0.620 |
Why?
|
| Mindfulness | 1 | 2020 | 70 | 0.600 |
Why?
|
| Nurses | 1 | 2020 | 109 | 0.590 |
Why?
|
| Physicians | 2 | 2023 | 475 | 0.580 |
Why?
|
| Academic Performance | 1 | 2018 | 7 | 0.560 |
Why?
|
| School Admission Criteria | 1 | 2018 | 8 | 0.560 |
Why?
|
| Muscarinic Antagonists | 2 | 2010 | 33 | 0.530 |
Why?
|
| Protective Agents | 1 | 2016 | 12 | 0.500 |
Why?
|
| Drug Therapy | 1 | 2016 | 56 | 0.490 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 767 | 0.470 |
Why?
|
| Parathion | 3 | 2012 | 5 | 0.460 |
Why?
|
| Medical Marijuana | 1 | 2014 | 19 | 0.440 |
Why?
|
| Agrobacterium | 1 | 2014 | 1 | 0.430 |
Why?
|
| Respiratory Insufficiency | 3 | 2012 | 155 | 0.410 |
Why?
|
| Automobile Driving | 1 | 2014 | 55 | 0.410 |
Why?
|
| Physostigmine | 2 | 2010 | 3 | 0.410 |
Why?
|
| Acetaminophen | 3 | 2008 | 58 | 0.400 |
Why?
|
| Hydrolases | 1 | 2014 | 82 | 0.400 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.400 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 10 | 0.400 |
Why?
|
| Clinical Competence | 1 | 2018 | 730 | 0.390 |
Why?
|
| Quality Improvement | 3 | 2015 | 446 | 0.390 |
Why?
|
| Cost Savings | 1 | 2013 | 53 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 237 | 0.370 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 2196 | 0.370 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 61 | 0.370 |
Why?
|
| Clinical Protocols | 1 | 2013 | 134 | 0.370 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2008 | 36 | 0.350 |
Why?
|
| Respiratory Muscles | 1 | 2010 | 16 | 0.340 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 36 | 0.340 |
Why?
|
| Burnout, Professional | 2 | 2023 | 134 | 0.340 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 29 | 0.340 |
Why?
|
| Humans | 39 | 2025 | 63635 | 0.340 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 39 | 0.340 |
Why?
|
| Methyl Parathion | 1 | 2010 | 3 | 0.340 |
Why?
|
| Writing | 2 | 2008 | 44 | 0.340 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 23 | 0.330 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2008 | 53 | 0.320 |
Why?
|
| Drug Overdose | 3 | 2008 | 131 | 0.320 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 47 | 0.310 |
Why?
|
| Video Recording | 2 | 2020 | 136 | 0.290 |
Why?
|
| Journal Impact Factor | 1 | 2008 | 26 | 0.290 |
Why?
|
| Toxicology | 1 | 2008 | 33 | 0.290 |
Why?
|
| Plagiarism | 1 | 2008 | 4 | 0.290 |
Why?
|
| Scientific Misconduct | 1 | 2008 | 12 | 0.290 |
Why?
|
| Ventricular Dysfunction | 1 | 2008 | 13 | 0.280 |
Why?
|
| Rats, Wistar | 6 | 2012 | 185 | 0.280 |
Why?
|
| Narcotics | 1 | 2008 | 58 | 0.270 |
Why?
|
| Editorial Policies | 1 | 2008 | 55 | 0.270 |
Why?
|
| Naloxone | 1 | 2008 | 61 | 0.270 |
Why?
|
| Documentation | 2 | 2006 | 128 | 0.270 |
Why?
|
| Suicide, Attempted | 1 | 2008 | 107 | 0.270 |
Why?
|
| Seizures | 2 | 2005 | 143 | 0.270 |
Why?
|
| Male | 21 | 2024 | 30004 | 0.260 |
Why?
|
| Methadone | 1 | 2008 | 134 | 0.260 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 153 | 0.260 |
Why?
|
| Aspirin | 1 | 2008 | 172 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 205 | 0.250 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 137 | 0.250 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 1105 | 0.240 |
Why?
|
| Computers, Handheld | 1 | 2006 | 38 | 0.240 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 917 | 0.240 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 175 | 0.240 |
Why?
|
| Emergency Treatment | 1 | 2006 | 58 | 0.240 |
Why?
|
| Ofloxacin | 1 | 2005 | 8 | 0.230 |
Why?
|
| Stillbirth | 1 | 2025 | 17 | 0.230 |
Why?
|
| Levofloxacin | 1 | 2005 | 13 | 0.230 |
Why?
|
| Phenylurea Compounds | 2 | 2023 | 31 | 0.230 |
Why?
|
| Rats | 7 | 2012 | 1982 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2008 | 269 | 0.230 |
Why?
|
| Alcoholism | 1 | 2008 | 317 | 0.220 |
Why?
|
| Gestational Age | 1 | 2025 | 191 | 0.220 |
Why?
|
| Female | 19 | 2025 | 33023 | 0.220 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 23 | 0.210 |
Why?
|
| Liver | 1 | 2008 | 860 | 0.200 |
Why?
|
| Personal Satisfaction | 2 | 2022 | 84 | 0.200 |
Why?
|
| Medical Errors | 2 | 2015 | 196 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 57 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 255 | 0.190 |
Why?
|
| Life Style | 2 | 2024 | 313 | 0.190 |
Why?
|
| Patient Safety | 2 | 2015 | 244 | 0.180 |
Why?
|
| Arm Injuries | 1 | 2001 | 12 | 0.180 |
Why?
|
| Leg Injuries | 1 | 2001 | 16 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 171 | 0.180 |
Why?
|
| Acute Disease | 2 | 2016 | 672 | 0.180 |
Why?
|
| Quinolines | 1 | 2022 | 45 | 0.180 |
Why?
|
| Animals | 11 | 2016 | 20694 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 448 | 0.180 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 62 | 0.180 |
Why?
|
| Pralidoxime Compounds | 2 | 2014 | 2 | 0.180 |
Why?
|
| Medicaid | 1 | 2025 | 362 | 0.180 |
Why?
|
| Middle Aged | 12 | 2024 | 17712 | 0.180 |
Why?
|
| Social Skills | 1 | 2020 | 10 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2015 | 6698 | 0.170 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 509 | 0.170 |
Why?
|
| Half-Life | 2 | 2010 | 80 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2001 | 345 | 0.160 |
Why?
|
| Melanoma | 1 | 2024 | 331 | 0.160 |
Why?
|
| Algorithms | 1 | 2025 | 1005 | 0.160 |
Why?
|
| Adult | 11 | 2025 | 16902 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 102 | 0.150 |
Why?
|
| Biomarkers | 1 | 2024 | 1410 | 0.150 |
Why?
|
| Pain | 1 | 2001 | 407 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2019 | 160 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 316 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 722 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 864 | 0.140 |
Why?
|
| Massachusetts | 4 | 2014 | 2075 | 0.140 |
Why?
|
| Acetylcysteine | 2 | 2008 | 26 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2022 | 586 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 684 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Mental Health | 1 | 2020 | 371 | 0.130 |
Why?
|
| Pediatrics | 1 | 2019 | 257 | 0.130 |
Why?
|
| General Surgery | 1 | 2019 | 213 | 0.130 |
Why?
|
| Acetylcholinesterase | 2 | 2014 | 15 | 0.120 |
Why?
|
| Diazepam | 2 | 2006 | 10 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1667 | 0.110 |
Why?
|
| Random Allocation | 3 | 2006 | 199 | 0.110 |
Why?
|
| Peer Review, Health Care | 1 | 2014 | 17 | 0.110 |
Why?
|
| Dronabinol | 1 | 2014 | 32 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2013 | 5712 | 0.110 |
Why?
|
| Depression, Chemical | 1 | 2014 | 11 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2014 | 3304 | 0.110 |
Why?
|
| Cannabinoids | 1 | 2014 | 41 | 0.110 |
Why?
|
| Cholinesterase Reactivators | 1 | 2014 | 1 | 0.110 |
Why?
|
| Respiratory Rate | 1 | 2014 | 15 | 0.110 |
Why?
|
| Chemical Warfare Agents | 1 | 2014 | 4 | 0.110 |
Why?
|
| Terrorism | 1 | 2014 | 16 | 0.110 |
Why?
|
| Hypothermia | 1 | 2013 | 17 | 0.110 |
Why?
|
| Sodium Acetate | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hospital Administration | 1 | 2014 | 43 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2014 | 144 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 136 | 0.100 |
Why?
|
| Disaster Planning | 1 | 2014 | 55 | 0.100 |
Why?
|
| Aged | 7 | 2022 | 14525 | 0.100 |
Why?
|
| Communication | 2 | 2020 | 580 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2014 | 149 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2014 | 339 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 63 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 299 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 322 | 0.090 |
Why?
|
| Soybean Oil | 1 | 2012 | 32 | 0.090 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2012 | 37 | 0.090 |
Why?
|
| Phospholipids | 1 | 2012 | 82 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 704 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2013 | 174 | 0.090 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2010 | 5 | 0.090 |
Why?
|
| Lung | 1 | 2016 | 955 | 0.090 |
Why?
|
| Creatine Kinase | 1 | 2010 | 41 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Diazonium Compounds | 1 | 2010 | 2 | 0.080 |
Why?
|
| Oximes | 1 | 2010 | 11 | 0.080 |
Why?
|
| Phosphoric Triester Hydrolases | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 41 | 0.080 |
Why?
|
| Azetidines | 1 | 2009 | 8 | 0.080 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 22 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 35 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 35 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2013 | 552 | 0.080 |
Why?
|
| Pyrroles | 1 | 2009 | 52 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2013 | 365 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 112 | 0.080 |
Why?
|
| Catalysis | 1 | 2010 | 162 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2701 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2010 | 155 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 203 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1557 | 0.070 |
Why?
|
| Copyright | 1 | 2008 | 1 | 0.070 |
Why?
|
| Lorazepam | 1 | 2008 | 8 | 0.070 |
Why?
|
| Free Radical Scavengers | 1 | 2008 | 21 | 0.070 |
Why?
|
| Anti-Anxiety Agents | 1 | 2008 | 32 | 0.070 |
Why?
|
| Hemofiltration | 1 | 2008 | 17 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2008 | 57 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.070 |
Why?
|
| Canada | 1 | 2008 | 154 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 141 | 0.070 |
Why?
|
| Risk | 1 | 2008 | 378 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 815 | 0.070 |
Why?
|
| Antiemetics | 1 | 2007 | 95 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2008 | 308 | 0.060 |
Why?
|
| Xylazine | 1 | 2006 | 3 | 0.060 |
Why?
|
| Utilization Review | 1 | 2006 | 32 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2006 | 55 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 2586 | 0.060 |
Why?
|
| Morphine | 1 | 2006 | 59 | 0.060 |
Why?
|
| Ketamine | 1 | 2006 | 38 | 0.060 |
Why?
|
| Florida | 1 | 2025 | 48 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 17 | 0.060 |
Why?
|
| Delirium | 1 | 2006 | 54 | 0.060 |
Why?
|
| Sodium Oxybate | 1 | 2004 | 2 | 0.060 |
Why?
|
| Harmaline | 1 | 2004 | 1 | 0.050 |
Why?
|
| Methoxydimethyltryptamines | 1 | 2004 | 1 | 0.050 |
Why?
|
| Bradycardia | 1 | 2004 | 33 | 0.050 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2004 | 10 | 0.050 |
Why?
|
| Registries | 1 | 2008 | 890 | 0.050 |
Why?
|
| Hallucinogens | 1 | 2004 | 14 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.050 |
Why?
|
| Hypotension | 1 | 2004 | 50 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 31 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2024 | 122 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 70 | 0.050 |
Why?
|
| Glycolates | 1 | 2023 | 3 | 0.050 |
Why?
|
| Ethylene Glycol | 1 | 2023 | 10 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2024 | 167 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 32 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 5501 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 137 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 47 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 50 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 53 | 0.050 |
Why?
|
| Cholestasis | 1 | 2002 | 66 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 467 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2023 | 197 | 0.040 |
Why?
|
| Health Behavior | 1 | 2024 | 472 | 0.040 |
Why?
|
| Patient Care | 1 | 2001 | 80 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 775 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 4717 | 0.040 |
Why?
|
| Time Factors | 1 | 2008 | 3770 | 0.040 |
Why?
|
| Internet | 1 | 2004 | 470 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 220 | 0.040 |
Why?
|
| United States | 2 | 2025 | 7867 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 6260 | 0.040 |
Why?
|
| Ethanol | 1 | 2023 | 322 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 370 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1152 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.040 |
Why?
|
| Pregnancy | 1 | 2025 | 2338 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 946 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 844 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 736 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 156 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2001 | 2576 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.030 |
Why?
|
| Risk Factors | 1 | 2005 | 5367 | 0.030 |
Why?
|
| Accidents | 1 | 2013 | 14 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 60 | 0.030 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 11 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2013 | 48 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 42 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 173 | 0.020 |
Why?
|
| Age Factors | 2 | 2009 | 1567 | 0.020 |
Why?
|
| Apnea | 1 | 2012 | 32 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 873 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 338 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2009 | 6 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 23 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 271 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 104 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1748 | 0.020 |
Why?
|
| Emulsions | 1 | 2012 | 474 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2009 | 246 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 245 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1999 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 21 | 0.020 |
Why?
|
| Metoclopramide | 1 | 2007 | 12 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 738 | 0.020 |
Why?
|
| Ondansetron | 1 | 2007 | 33 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 312 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2006 | 100 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 618 | 0.010 |
Why?
|
| Deception | 1 | 2004 | 6 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 2004 | 13 | 0.010 |
Why?
|
| Child | 1 | 2013 | 4537 | 0.010 |
Why?
|
| Seeds | 1 | 2004 | 31 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 145 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2004 | 162 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 239 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2004 | 116 | 0.010 |
Why?
|
| Chromans | 1 | 2002 | 16 | 0.010 |
Why?
|
| Transaminases | 1 | 2002 | 14 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2002 | 40 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 46 | 0.010 |
Why?
|